The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Abstract
CONTEXT: Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion, and weight loss is a consistent associated finding. OBJECTIVES: Our objectives were to confirm weight loss with dapagliflozin and establish through body composition measurements whether weight loss is accounted for by changes in fat or fluid components. DESIGN AND SETTING: This was a 24-wk, international, multicenter, randomized, parallel-group, double-blind, placebo-controlled study with ongoing 78-wk site- and patient-blinded extension period at 40 sites in five countries. PATIENTS: Included were 182 patients with T2DM (mean values: women 63.3 and men 58.6 yr of age; hemoglobin A1c 7.17%, body mass index 31.9 kg/m2, and body weight 91.5 kg) inadequately controlled on metformin. INTERVENTION: Dapagliflozin 10 mg/d or placebo was added to open-label metformin for 24 wk. MAIN OUTCOME MEASURES: Primary endpoint was total body weight (TBW) change from baseline at wk 24. Key secondary endpoints were waist circumference and dual-energy x-ray absorptiometry total-body fat mass (FM) changes from baseline at wk 24, and patient proportion achieving body weight reduction of at least 5% at wk 24. In a subset of patients, magnetic resonance assessment of visceral adipose tissue (VAT) and sc adipose tissue (SAT) volume and hepatic lipid content were also evaluated. RESULTS: At wk 24, placebo-corrected changes with dapagliflozin were as follows: TBW, -2.08 kg [95% confidence interval (CI)=-2.84 to -1.31; P<0.0001]; waist circumference, -1.52 cm (95% CI=-2.74 to -0.31; P=0.0143); FM, -1.48 kg (95% CI=-2.22 to -0.74; P=0.0001); proportion of patients achieving weight reduction of at least 5%, +26.2% (95% CI=15.5 to 36.7; P<0.0001); VAT, -258.4 cm3 (95% CI=-448.1 to -68.6; nominal P=0.0084); SAT, -184.9 cm3 (95% CI=-359.7 to -10.1; nominal P=0.0385). In the dapagliflozin vs. placebo groups, respectively, serious adverse events were reported in 6.6 vs. 1.1%; events suggestive of vulvovaginitis, balanitis, and related genital infection in 3.3 vs. 0%; and lower urinary tract infections in 6.6 vs. 2.2%. CONCLUSIONS: Dapagliflozin reduces TBW, predominantly by reducing FM, VAT and SAT in T2DM inadequately controlled with metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Grundy, S. M. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.151092 · Cited by 1,616
de Koning, L., Merchant, A. T., Pogue, J., & Anand, S. S. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm026 · Cited by 1,073
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 873
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 725
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629
Research works printed but not linked: 1
- Tang, 2003, The financing burden of treatment of diabetes-II and its symptom in urban China., Chin Health Econ, 12, 21
Cited by
Sorted by citations
Items 101–200 of 864
Seferovic, P. M., Fragasso, G., Petrie, M. C., Müllens, W., Ferrari, R., Thum, T., Bauersachs, J. K., Anker, S. D., Ray, R., Çavuşoğlu, Y., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1954 · Cited by 136
Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity
Iacobellis, G., & Gra‐Menendez, S. (2020) · Obesity · doi:10.1002/oby.22798 · Cited by 130
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A. D., Koliaki, C. C., & Mantzoros, C. S. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 141
Zhang, M., Zhang, L., Wu, B., Song, H.-L., An, Z., & Li, S. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2479 · Cited by 129
Takeshita, Y., Honda, M., Harada, K., Kita, Y., Takata, N., Tsujiguchi, H., Tanaka, T., Goto, H., Nakano, Y., Iida, N., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2049 · Cited by 131
Ptaszynska, A., Johnsson, K. M., Parikh, S. J., de Bruin, T. W., Apanovitch, A. M., & List, J. F. (2014) · Drug Safety · doi:10.1007/s40264-014-0213-4 · Cited by 126
Self-citationWeber, M. A., Mansfield, T. A., Alessi, F., Iqbal, N., Parikh, S. J., & Ptaszynska, A. (2015) · Blood Pressure · doi:10.3109/08037051.2015.1116258 · Cited by 123
Self-citationKidney-Protective Effects of SGLT2 Inhibitors
Palmer, B. F., & Clegg, D. J. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09380822 · Cited by 128
Fukuda, T., Bouchi, R., Terashima, M., Sasahara, Y., Asakawa, M., Takeuchi, T., Nakano, Y., Murakami, M., Minami, I., Izumiyama, H., et al. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0279-y · Cited by 126
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
Alicic, R. Z., Neumiller, J. J., Johnson, E. J., Dieter, B. P., & Tuttle, K. R. (2019) · Diabetes · doi:10.2337/dbi18-0007 · Cited by 125
Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review
Konwerski, M., Gąsecka, A., Opolski, G., Grabowski, M., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11030355 · Cited by 132
Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy
Palmer, B. F., & Clegg, D. J. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.17621120 · Cited by 134
Fadini, G. P., Bonora, B. M., Zatti, G., Vitturi, N., Iori, E., Marescotti, M. C., Albiero, M., & Avogaro, A. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0529-3 · Cited by 126
Wilding, J. P. H., Ferrannini, E., Fonseca, V. A., Wilpshaar, W., Dhanjal, P., & Houzer, A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12038 · Cited by 117
Self-citationEnergy balance and metabolic changes with sodium‐glucose co‐transporter 2 inhibition
Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12578 · Cited by 117
Self-citationDECLARE‐TIMI 58: Participants’ baseline characteristics
Raz, I., Mosenzon, O., Bonaca, M. P., Cahn, A., Kato, E. T., Silverman, M. G., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13217 · Cited by 119
Self-citationScheen, A. J., & Paquot, N. (2014) · Diabetes & Metabolism · doi:10.1016/s1262-3636(14)72689-8 · Cited by 114
Effects of Dapagliflozin on Cardiovascular Risk Factors
Ptaszynska, A., Hardy, E., JOHNSSON, E. K., Parikh, S. J., & List, J. F. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2667 · Cited by 115
Self-citationInsulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113
Nauck, M. A., Prato, S. D., Durán-Garcia, S., Rohwedder, K., Langkilde, A. M., Sugg, J. E., & Parikh, S. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12327 · Cited by 114
Self-citationSGLT-2 inhibitors and their potential in the treatment of diabetes
Epstein, B. J., Rosenwasser, R., SUTTON, D. R., Choksi, R. R., & Sultan (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s34416 · Cited by 119
Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis
Masson, W. M., Cobo, A. L., & Nogueira, J. P. (2021) · Cells · doi:10.3390/cells10082150 · Cited by 118
Xie, X., Wu, C., Hao, Y., Wang, T., Yang, Y., Cai, P., Zhang, Y., Huang, J., Deng, K., Yan, D., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301093 · Cited by 129
Xu, L., Nagata, N., Chen, G., Nagashimada, M., Zhuge, F., Ni, Y., Sakai, Y., Kaneko, S., & Ota, T. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000783 · Cited by 109
Lundkvist, P., Sjöström, C. D., Amini, S., Pereira, M. J., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12779 · Cited by 108
Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes
Sugiyama, S., Jinnouchi, H., Kurinami, N., Hieshima, K., Yoshida, A., Jinnouchi, K., Nishimura, H., Suzuki, T., MIYAMOTO, F., Kajiwara, K., et al. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.40873 · Cited by 115
Brown, E. E., Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13650 · Cited by 107
Self-citationInoue, M., Hayashi, A., Taguchi, T., Arai, R., Sasaki, S., Takano, K., Inoue, Y., & Shichiri, M. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12980 · Cited by 108
Sodium glucose cotransporter 2 inhibition in the diabetic kidney
Novikov, A., & Vallon, V. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000187 · Cited by 106
Kaku, K., Kiyosue, A., Inoue, S., Ueda, N., Tokudome, T., Yang, J., & Langkilde, A. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12325 · Cited by 103
Self-citationDapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes
Plosker, G. L. (2014) · Drugs · doi:10.1007/s40265-014-0324-3 · Cited by 108
A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome
Abdalla, M. A., Deshmukh, H., Atkin, S. L., & Sathyapalan, T. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820938305 · Cited by 115
Phrueksotsai, S., Pinyopornpanish, K., Euathrongchit, J., Leerapun, A., Phrommintikul, A., Buranapin, S., Chattipakorn, N., & Thongsawat, S. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15580 · Cited by 104
Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
Madaan, T., Akhtar, M., & Najmi, A. K. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.08.025 · Cited by 106
Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
Kaplan, A., Abidi, E., EL‐Yazbi, A. F., Eid, A. H., Booz, G. W., & Zouein, F. A. (2018) · Heart Failure Reviews · doi:10.1007/s10741-017-9665-9 · Cited by 108
Ortega, R., Collado, A., Selles, F., Navarro, H. G., Sanz, M., Real, J. T., & Piqueras, L. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312659 · Cited by 102
Bays, H. E. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0042-y · Cited by 107
Fioretto, P., Giaccari, A., & Sesti, G. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0297-x · Cited by 104
Packer, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13229 · Cited by 105
Plosker, G. L. (2012) · Drugs · doi:10.2165/11209910-000000000-00000 · Cited by 99
ESTERLINE, R. L., Vaag, A. A., Oscarsson, J., & Vora, J. P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0832 · Cited by 97
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
Tang, J., Ye, L., Yan, Q., Zhang, X., & Wang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.800490 · Cited by 106
Suzuki, M., Takeda, M., Kito, A., Fukazawa, M., Yata, T., Yamamoto, M., Nagata, T., Fukuzawa, T., Yamane, M., Honda, K., et al. (2014) · Nutrition and Diabetes · doi:10.1038/nutd.2014.20 · Cited by 97
SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
Wilding, J. P. H., Fernando, K., Milne, N., Evans, M., Ali, A., Bain, S. C., Hicks, D., James, J., Newland‐Jones, P., Patel, D., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0471-8 · Cited by 101
Self-citationElkind-Hirsch, K. E., Chappell, N., Seidemann, E., Storment, J., & Bellanger, D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab408 · Cited by 96
Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice
Millar, P., Pathak, N., Parthsarathy, V., Bjourson, A. J., O’Kane, M., Pathak, V., Moffett, R. C., Flatt, P. R., & Gault, V. A. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0263 · Cited by 96
SGLT2 inhibitors: their potential reduction in blood pressure
Maliha, G., & Townsend, R. R. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.11.001 · Cited by 94
SGLT2 Inhibitors and Mechanisms of Hypertension
Briasoulis, A., Al Dhaybi, O., & Bakris, G. L. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0943-5 · Cited by 94
Pharmacological treatment and therapeutic perspectives of metabolic syndrome
Lim, S. K., & Eckel, R. H. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9298-4 · Cited by 98
Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications
Zhang, X., Zhao, Y., Chen, S., & Shao, H. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12838 · Cited by 96
Management of Obesity in Cardiovascular Practice
Després, J.-P., Carpentier, A. C., Tchernof, A., Neeland, I. J., & Poirier, P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.035 · Cited by 87
Fonseca, V. A., Ferrannini, E., Wilding, J. P. H., Wilpshaar, W., Dhanjal, P., Ball, G., & Klasen, S. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.11.005 · Cited by 86
Self-citationA Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
Jung, C. H., Jang, J. E., & Park, J. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.4.261 · Cited by 88
Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus
Ida, S., Kaneko, R., Imataka, K., Okubo, K., Shirakura, Y., Azuma, K., Fujiwara, R., & Murata, K. (2021) · Current Diabetes Reviews · doi:10.2174/1573399816666200705210006 · Cited by 85
Berhan, A., & Barker, A. J. (2013) · BMC Endocrine Disorders · doi:10.1186/1472-6823-13-58 · Cited by 85
Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes
Zou, C., Liu, X., Sang, Y., Wang, B., & Liang, J. (2019) · Medicine · doi:10.1097/md.0000000000018245 · Cited by 87
Giorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01163-9 · Cited by 88
Kashiwagi, A., Kazuta, K., Takinami, Y., Yoshida, S., Utsuno, A., & Nagase, I. (2014) · Diabetology International · doi:10.1007/s13340-014-0164-0 · Cited by 84
Zhang, S., Qi, Z., Wang, Y., Song, D., & Zhu, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1203666 · Cited by 87
Seidu, S., Kunutsor, S. K., Cos, X., Gillani, S., & Khunti, K. (2018) · Primary Care Diabetes · doi:10.1016/j.pcd.2018.02.001 · Cited by 82
Washburn, W. N., & Poucher, S. M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.774372 · Cited by 81
Kashiwagi, A., & Maegawa, H. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12644 · Cited by 80
Sugiyama, S., Jinnouchi, H., Kurinami, N., Hieshima, K., Yoshida, A., Jinnouchi, K., Nishimura, H., Suzuki, T., MIYAMOTO, F., Kajiwara, K., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0701-17 · Cited by 86
Pharmacotherapy for childhood obesity: present and future prospects
Sherafat‐Kazemzadeh, R., Yanovski, S. Z., & Yanovski, J. A. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.144 · Cited by 83
Tanizawa, Y., Kaku, K., Araki, E., Tobe, K., Terauchi, Y., Utsunomiya, K., Iwamoto, Y., Watada, H., Ohtsuka, W., Watanabe, D., et al. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.887680 · Cited by 80
Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
Schönberger, E., Mihaljević, V., Steiner, K., Šarić, S., Kurevija, T., Majnarić, L. T., Bilić-Čurčić, I., & Canecki-Varžić, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20176671 · Cited by 87
SGLT2 inhibitors in the management of type 2 diabetes
Reddy, R. P. M., & Inzucchi, S. E. (2016) · Endocrine · doi:10.1007/s12020-016-0943-4 · Cited by 80
The effect of dapagliflozin on renal function in patients with type 2 diabetes
Kohan, D. E., Fioretto, P., Johnsson, K. M., Parikh, S. J., Ptaszynska, A., & Ying, L. (2016) · Journal of Nephrology · doi:10.1007/s40620-016-0261-1 · Cited by 78
Self-citationSun, Y.-N., Zhou, Y., Chen, X., Che, W.-S., & Leung, S.-W. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004619 · Cited by 77
The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
Fattah, H., & Vallon, V. (2018) · Drugs · doi:10.1007/s40265-018-0901-y · Cited by 77
Mosley, J., Smith, L., Everton, E. C., & Fellner, C. (2015) · PubMed Central · Cited by 75
Han, E., Lee, Y., Lee, B., Kang, E. S., & Soo, B. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010259 · Cited by 81
Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 76
Strojek, K., Yoon, K., Hrubá, V., Sugg, J. E., Langkilde, A. M., & Parikh, S. J. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0072-0 · Cited by 75
Self-citationBays, H. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.029 · Cited by 73
Ikeda, S., Takano, Y., Cynshi, O., Tanaka, R., Christ, A. D., Boerlin, V., Beyer, U., Beck, A., Ciorciaro, C., Meyer, M., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12538 · Cited by 73
Tang, H., Fang, Z., Wang, T., Cui, W., Zhai, S., & Song, Y. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.08.061 · Cited by 73
Tang, Y., Sun, Q., Bai, X., Zhou, Y., Zhou, Q.-L., & Zhang, M. (2019) · Nutrition and Diabetes · doi:10.1038/s41387-019-0098-5 · Cited by 73
Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
Babu, A. R., Kim, S., & Babu, A. R. (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s22545 · Cited by 71
Imprialos, K. P., Sarafidis, P. A., & Karagiannis, A. I. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000719 · Cited by 71
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 74
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1100167 · Cited by 70
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
Dekkers, C. C. J., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0992-6 · Cited by 76
Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
Campos-Murguía, A., Ruiz‐Margáin, A., González-Regueiro, J. A., & Macías‐Rodríguez, R. U. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i39.5919 · Cited by 75
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Cusi, K. J. (2020) · Diabetes Care · doi:10.2337/dci19-0064 · Cited by 71
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents
Vivian, E. (2014) · Drugs in Context · doi:10.7573/dic.212264 · Cited by 70
Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation
Naaman, S., Shen, S., Zeytinoglu, M., & Iyengar, N. M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac241 · Cited by 71
Chen, L., & Leung, P. S. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12064 · Cited by 67
Cai, X., Ji, L., Chen, Y., Yang, W., Zhou, L., Han, X., Zhang, S., & Ji, L. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12625 · Cited by 65
The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
Brown, E. E., Wilding, J. P. H., Alam, U., Barber, T. M., Karalliedde, J. J., & Cuthbertson, D. J. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1841281 · Cited by 69
Self-citationA Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 71
Seidu, S., Alabraba, V., Davies, S., Newland‐Jones, P., Fernando, K., Bain, S. C., Diggle, J., Evans, M., James, J., Kanumilli, N., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01550-5 · Cited by 82
Self-citationCai, X., Gao, X., Yang, W., Chen, Y., Zhang, S., Zhou, L., Han, X., & Ji, L. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12760 · Cited by 64
Herrington, W. G., Savarese, G., Haynes, R., Marx, N., Mellbin, L., Lund, L. H., Dendale, P., Seferovic, P. M., Rosano, G. M. C., Staplin, N., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2286 · Cited by 66
Inoue, H., Morino, K., Ugi, S., Tanaka‐Mizuno, S., Fuse, K., Miyazawa, I., Kondo, K., Sato, D., Ohashi, N., Ida, S., et al. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12985 · Cited by 64
Tang, W., Xu, Q., Hong, T., Tong, G., Feng, W., Shen, S., Bi, Y., & Zhu, D. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2713 · Cited by 63
Vickers, S. P., Cheetham, S. C., Headland, K. R., Dickinson, K., Grempler, R., Mayoux, E., Mark, M., & Klein, T. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s58786 · Cited by 62
Reilly, T. P., Graziano, M. J., Janovitz, E. B., Dorr, T. E., Fairchild, C. R., Lee, F. Y., Chen, J., Wong, T., Whaley, J. M., & Tirmenstein, M. A. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0053-3 · Cited by 63
Schumm‐Draeger, P. ‐., Burgess, L. J., Koranyi, L. I., Hrubá, V., Hamer-Maansson, J. E., & de Bruin, T. W. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12387 · Cited by 65
Miyachi, Y., Tsuchiya, K., Shiba, K., Mori, K., Komiya, C., Ogasawara, N., & Ogawa, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-34305-x · Cited by 62
Metadata
- Authors
- Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S.
- Affiliations
- Karolinska University Hospital (SE)
- Uppsala University Hospital (SE)
- Aintree University Hospital (GB)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- Corresponding author
- Bolinder, Jan
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-03-01
- Volume
- 97
- Issue
- 3
- Pages
- 1020-1031
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2167245776
- Cited by
- 867
- References
- 36
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 51 · 2023: 76 · 2022: 76 · 2021: 70 · 2020: 85 · 2019: 54 · 2018: 53 · 2017: 72 · 2016: 62 · 2015: 53 · 2014: 79 · 2013: 42 · 2012: 17
- FWCI
- 48.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, weight loss, body composition, fat mass, visceral adipose tissue, subcutaneous adipose tissue, hepatic fat content, metformin, inadequate glycemic control, waist circumference, fluid balance, urinary glucose excretion, glycemic control
- MeSH terms
- Adipose Tissue, Adult, Aged, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucosides, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Body Mass Index, Treatment Outcome, Body Fat Distribution, Sodium-Glucose Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
